Atamyo Therapeutics develops gene replacement therapies specifically targeting limb-girdle muscular dystrophies (LGMDs) through tailored delivery systems that minimize side effects and enhance physiological function restoration. The company addresses the unmet medical need for effective treatments in patients suffering from rare genetic neuromuscular disorders.
Funding
Funding not disclosed
EAFounders
Product
Problem
Limb-girdle muscular dystrophies (LGMDs) are a group of rare, progressive genetic disorders that cause muscle weakness and atrophy, primarily affecting the shoulder and pelvic areas. These conditions lead to significant mobility issues and reduced quality of life, with limited treatment options available. Current management strategies are largely supportive, failing to address the underlying genetic causes of the disease.
Solution
Atamyo Therapeutics develops gene replacement therapies designed to address the root causes of specific LGMD subtypes. The company focuses on creating tailored delivery systems using adeno-associated virus (AAV) vectors to minimize side effects and maximize the restoration of normal physiological function in affected muscles. Their approach involves delivering a functional copy of the mutated gene to produce the necessary proteins, aiming to slow or halt disease progression. Atamyo's lead programs target LGMD-R9/2I and LGMD-2C/R5, both of which currently lack curative treatments. These therapies have received Orphan Drug Designation from regulatory agencies, highlighting their potential to address unmet medical needs.
Target Audience
The primary target audience includes patients diagnosed with specific subtypes of limb-girdle muscular dystrophy (LGMD), their families, and the physicians specializing in neuromuscular disorders.
Features
- AAV-based gene therapies targeting specific LGMD subtypes, including LGMD-R9/2I and LGMD-2C/R5
- Tailored delivery systems designed to enhance gene transfer efficiency and minimize off-target effects
- ATA-100: A gene therapy in Phase 1/2 clinical trials for LGMD-R9/2I, delivering a functional copy of the FKRP gene
- ATA-200: A gene therapy with IND clearance to proceed to clinical trials for LGMD-2C/R5, delivering a normal copy of the γ-sarcoglycan gene
- Proprietary AAV capsid (LICA-1) for improved myotropism and reduced immunogenicity
- Clinical trials evaluating safety, pharmacodynamics, efficacy, and immunogenicity
- Biomarker identification studies to monitor treatment response and disease progression